BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, November 11, 2013
At least 18 biotechs and pharmas reported earnings
last week. Two companies - Endo Health Solutions Inc. (NASDAQ:ENDP) and
Salix Pharmaceuticals Inc. (NASDAQ:SLXP) - beat the Street's EPS estimates
and announced acquisitions. Endo added 37% last week after it said it would
acquire Canadian specialty pharma Paladin Labs Inc. (TSX:PLB) (see
B5). Salix gained 15% after announcing plans to acquire fellow
gastrointestinal company Santarus Inc. (NASDAQ:SNTS) (see A17).
Santarus, which also reported strong earnings last week, closed up 35%
on the week.
Cancer diagnostics company Genomic Health Inc.
(NASDAQ:GHDX) jumped 21% last week after beating the Street's EPS and revenue
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]